AstraZeneca Takes HUTCHMED’s Lung Cancer Combination to the US FDA

The application addresses one of the major challenges in treating EGFR-mutated non-small cell lung cancer. EGFR-targeted drugs such as TAGRISSO have substantially improved outcomes for patients, but tumors can eventually develop mechanisms that allow them to resist treatment. MET overexpression or amplification is among the important resistance pathways observed after EGFR tyrosine kinase inhibitor therapy. Savolitinib is designed to inhibit MET, while osimertinib continues suppressing the EGFR pathway. Combining the two therefore attacks both the original oncogenic driver and an important mechanism of treatment resistance. The proposed treatment is also fully oral, potentially providing an alternative to platinum-based chemotherapy for appropriately selected patients.

The regulatory filing is supported primarily by the global Phase III SAFFRON trial, which compared savolitinib plus osimertinib with platinum-based doublet chemotherapy in patients whose EGFR-mutated tumors had high MET overexpression or amplification after progression on TAGRISSO. AstraZeneca reported in August that the combination delivered statistically significant and clinically meaningful improvements in both progression-free survival and overall survival, with no new safety concerns identified. Detailed SAFFRON data are expected to be presented at the 2026 European Society for Medical Oncology Congress. Earlier evidence from China had already strengthened the case for the combination. In the Phase III SACHI trial involving 211 patients, median progression-free survival reached 8.2 months with savolitinib plus osimertinib compared with 4.5 months for chemotherapy, representing a 66% reduction in the risk of disease progression or death. China approved the combination in June 2025 for EGFR-mutated, MET-amplified advanced lung cancer following progression on EGFR inhibitor therapy.

The commercial implications are meaningful for both companies. TAGRISSO is already one of AstraZeneca’s most important oncology products, generating $3.78 billion in global sales during the first half of 2026, an increase of 8% from a year earlier. US sales alone reached about $1.58 billion. Adding a biomarker-directed combination for patients who become resistant to TAGRISSO could help AstraZeneca extend the drug’s role further across the treatment pathway rather than losing patients immediately to chemotherapy after progression. For HUTCHMED, the economics are different but potentially significant. Under its long-running savolitinib collaboration with AstraZeneca, HUTCHMED is eligible for development and commercial milestone payments and tiered royalties on sales outside China. HUTCHMED has said these overseas royalties generally range from 9% to 13%, while AstraZeneca takes responsibility for global development and commercialization outside China. ORPATHYS-related revenue at HUTCHMED reached $13.3 million in the first half of 2026, up 48% year on year, although the drug remains a relatively small contributor compared with the potential scale of a successful US launch.

The filing also reflects a broader shift in China’s biotechnology industry. Chinese drug developers increasingly pursue global value creation not by building full commercial operations in every overseas market, but by discovering and advancing differentiated molecules domestically before partnering with multinational pharmaceutical groups that have established regulatory, clinical and distribution infrastructure. HUTCHMED’s relationship with AstraZeneca dates back to 2011, making savolitinib one of the longer-running examples of this model. An FDA approval would therefore have implications beyond a single lung cancer treatment: it would provide another example of a China-originated oncology asset reaching a major global market through cross-border co-development. The application itself does not guarantee approval, and the FDA still has to formally review the efficacy, safety, biomarker-selection and manufacturing package. Nevertheless, the transition from Chinese approval to a global Phase III-supported US filing marks a significant step in the internationalization of China’s innovative pharmaceutical sector.